Proxy Votes Now

Home › Funds › ProShares › ProShares Ultra Health Care

ProShares Ultra Health Care (RXL) proxy voting record 2025-2026

Fund family: ProShares · Filed by PROSHARES TRUST (CIK 1174610) · SEC series S000014253

Ticker: RXL (C000038812)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 733 with, 33 against, 0 abstentions (not counted as with management). Shareholder proposals: 14 FOR, 19 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with ProShares as a whole

The same two figures as ProShares’s manager page (303,945 ballot items across 135 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsProSharesItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)97.5%71591.4%279,029
Backed environmental and social shareholder proposals at US companiesn/a910.6%4,043

Where this fund voted differently from most ProShares funds

Each ballot item this fund voted is set against the votes of the other ProShares funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most ProShares funds on all 746 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 100.0% of this fund’s 766 such votes could be given a sector.

SectorVotesAgainst managementShare
Health Care675314.6%
Industrials7411.4%
Consumer Staples1715.9%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections5630
Say-on-Pay630
Audit-related620
Corporate Governance3622
Compensation222
Capital Structure70
Other Social Issues55
Shareholder Rights and Defenses40
Environment or Climate33
Extraordinary Transactions20

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$13M102
Johnson & JohnsonApril 23, 2026$8M151
AbbVie Inc.May 8, 2026$6M81
UnitedHealth Group IncorporatedJune 1, 2026$4M121
Merck & Co., Inc.May 26, 2026$4M183
Thermo Fisher Scientific Inc.May 20, 2026$3M130
Amgen Inc.May 19, 2026$3M151
Gilead Sciences, Inc.April 30, 2026$2M153

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalForAgainst
June 1, 2026UnitedHealth Group IncorporatedIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 23, 2026Pfizer Inc.Adopt an Independent Chair Policy Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst

Funds that vote the same way

These funds reported the same votes as ProShares Ultra Health Care in the latest season (or all but a few items), so they share this page:

Search this fund’s votes by company

768 ballot items at 63 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, ProShares Ultra Health Care (RXL) voted at 63 shareholder meetings of 60 companies, on 768 ballot items in all. Where management made a recommendation, the fund followed it on 95.7% of the items and voted against it 33 times. Its most frequent area of disagreement was corporate governance (22 of its votes against management). It voted on 33 shareholder proposals. It voted FOR the board's own proposals more often than ProShares's funds as a whole (97.5% against 91.4%). It voted the same way as most ProShares funds on every item where a comparison was possible.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of ProShares’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.